Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lisocabtagene-maraleucel (Primary)
Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Leukaemia; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms PLAT-02

12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
15 Feb 2022 Planned End Date changed from 1 Sep 2035 to 1 Jul 2036.
01 Jan 2022 Results evaluating the effect of consolidative HCT on LFS in pediatric and young adult subjects treated with a 41BB-CD19 CAR T cell product on this phase 1/2 trial published in the Transplantation and Cellular Therapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com